Share chart Xeris Pharmaceuticals, Inc.
Extended chart
Simple chart
About
Xeris Pharmaceuticals, Inc., специализированная фармацевтическая компания, разрабатывает и продает готовые к употреблению инъекционные и инфузионные лекарственные формы. Его запатентованные технологические платформы XeriSol и XeriJect позволяют осуществлять подкожную и внутримышечную доставку высококонцентрированных, готовых к использованию рецептур пептидов, небольших молекул и белков с помощью имеющихся в продаже шприцев, автоинжекторов, многодозовых ручек и инфузий. насосы. more details| IPO date | 2018-06-21 |
|---|---|
| ISIN | US98422E1038 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.xerispharma.com |
| Цена ао | 3.27 |
| Change price per day: | -3.82% (3.4) |
|---|---|
| Change price per week: | -7.63% (3.54) |
| Change price per month: | -3.82% (3.4) |
| Change price per 3 month: | +10.1% (2.97) |
| Change price per half year: | +33.47% (2.45) |
| Change price per year: | +18.05% (2.77) |
| Change price per 3 year: | +54.25% (2.12) |
| Change price per 5 year: | -46.13% (6.07) |
| Change price per 10 year: | 0% (3.27) |
| Change price per year to date: | -6.3% (3.49) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Blackrock Inc. | 10 | 6.72 |
| Vanguard Group Inc | 8 | 5.13 |
| Caxton Corporation | 5 | 3.45 |
| MPM BioImpact Capital LLC | 4 | 2.81 |
| State Street Corporation | 3 | 2.17 |
| Geode Capital Management, LLC | 3 | 2.05 |
| Rosalind Advisors, Inc. | 3 | 1.9 |
| Millennium Management LLC | 2 | 1.14 |
| Nuveen Asset Management, LLC | 2 | 1.07 |
| CenterBook Partners LP | 2 | 1.04 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| SPDR S&P Pharmaceuticals ETF | 0.44148 | 29.8 | 1.29889 |
| Direxion Daily Pharmaceutical & Medical Bull 3X Shares | 0.36397 | 86.72 | 1.2989 |
| iShares Micro-Cap ETF | 0.10416 | 13.79 | 1.54048 |
| Invesco Nasdaq Biotechnology ETF | 0.04226 | 28.58 | 0.8565 |
| Principal Healthcare Innovators ETF | 0.04102 | 618.5 | 0.8416 |
| Future Tech ETF | 0.04102 | 426.34 | 0.8416 |
| Principal U.S. Small-Cap ETF | 0.0403 | 14.66 | 1.20466 |
iShares Russell 2000 Growth ETF
|
0.03019 | 38.04 | 0.6026 |
| Vanguard Russell 2000 Growth ETF | 0.03 | 17.39 | 0.60264 |
| ProShares Ultra Nasdaq Biotechnology | 0.02857 | 51.7 | 0.85651 |
| Goldman Sachs ActiveBeta US Small Cap Equity ETF | 0.02509 | 31.36 | 1.41955 |
| Vanguard Russell 2000 ETF | 0.01 | 14.37 | 1.48801 |
ProShares UltraPro Russell2000
|
0.00888 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.00248 | 5.92 | 1.47892 |
| iShares Russell 3000 ETF | 0.0005 | 23.61 | 1.43482 |
| Avantis U.S. Equity ETF | 0 | 20.45 | 1.59151 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Paul R. Edick | Senior Advisor | 1.12M | 1956 (69 years) |
| Mr. John P. Shannon | CEO & Director | 827.72k | 1962 (63 years) |
| Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary | 638.31k | 1964 (61 year) |
| Mr. Steven M. Pieper | Chief Financial Officer | N/A | 1978 (47 years) |
| Ms. Allison Wey | Senior Vice President of Investor Relations & Corporate Communications | N/A | |
| Dr. Kenneth E. Johnson Pharm. D., Pharm.D. | Senior VP of Global Development & Medical Affairs | N/A | 1963 (62 years) |
| Mr. Kevin McCulloch | Chief Commercial Officer | N/A | |
| Mr. Brian Conner | SVP of Quality and Chief Compliance & Risk Officer | ||
| Ms. Kendal Korte | Senior Vice President of Human Resources |
Address: United States, Chicago, IL , 180 North LaSalle Street - open in Google maps, open in Yandex maps
Website: https://www.xerispharma.com
Website: https://www.xerispharma.com
